Search

Search Constraints

You searched for: Author/Creator Delarue, Richard

Search Results

1. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. (9th September 2016)

2. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. (August 2017)

3. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Issue 10044 (6th August 2016)

4. Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies. (23rd February 2018)

5. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T‐cell lymphoma. (30th May 2019)

6. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Issue 1 (January 2017)

7. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Issue 1 (29th October 2013)

8. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial. Issue 1 (19th July 2022)

9. Efficacy of 5‐Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. (14th October 2014)

10. Efficacy of 5‐Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. (14th October 2014)